BACKGROUND: Previous studies have found persistent overuse of imaging for clinical staging of men with low-risk prostate cancer. We aimed to determine imaging trends in three cohorts of men. METHODS: We analyzed imaging trends of men with prostate cancer who were a part of Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) (1998)(1999)(2000)(2001)(2002)(2003)(2004)(2005)(2006), were insured by Medicare (1998Medicare ( -2006, or privately insured (Ingenix database, 2002(Ingenix database, -2006. The rates of computed tomography (CT), magnetic resonance imaging (MRI) and bone scan (BS) were determined and time trends were analyzed by linear regression. For men in CaPSURE, demographic and clinical predictors of test use were explored using a multivariable regression model. RESULTS: Since 1998, there was a significant downward trend in BS (16%) use in the CaPSURE cohort (N ¼ 5156). There were slight downward trends (2.4 and 1.7%, respectively) in the use of CT and MRI. Among 54 322 Medicare patients, BS, CT and MRI use increased by 2.1, 10.8 and 2.2% and among 16 161 privately insured patients, use increased by 7.9, 8.9 and 3.7%, respectively. In CaPSURE, the use of any imaging test was greater in men with higher-risk disease. In addition, type of insurance and treatment affected the use of imaging tests in this population. CONCLUSIONS: There is widespread misuse of imaging tests in men with low-risk prostate cancer, particularly for CT. These findings highlight the need for examination of factors that drive decision making with respect to imaging in this setting.
INTRODUCTION
Few questions in prostate cancer research or clinical care are the subject of so little controversy as the non-utility of staging tests for low-risk prostate cancer. Guidelines dating to the mid-1990s from multiple international organizations have argued-consistently-that tests such as computed tomography (CT) and bone scan (BS) should be limited to men with intermediate-to high-risk disease characteristics, for example, PSA X20 ng ml À 1 , clinical stage XT3 and/or Gleason score X7. [1] [2] [3] [4] [5] Downward risk migration during the time since these guidelines were first developed and promulgated has been well documented, 6, 7 and some studies have found a concomitant decline in utilization of imaging tests. 8, 9 However, these studies and others also confirmed persistent overutilization in substantial proportions of men studied. [8] [9] [10] [11] [12] Indeed, a recent study of Medicare beneficiaries with prostate cancer determined that over the past decade, imaging use has increased by 2.5% for nuclear medicine, 4.6% for CT and 6.2% for magnetic resonance imaging (MRI). 13 Overall, imaging costs within 2 years of diagnosis have risen by 45% annually and account for a growing portion of prostate cancer expenditures. In addition, a growing number of studies support concern over the risks of accumulating radiation doses over time and development of secondary malignancies. 14, 15 We aimed to determine and confirm recently reported trends of imaging utilization in three large, contemporary cohorts of men with various stages of prostate cancer, and to assess demographic and clinical predictors of testing.
MATERIALS AND METHODS

Data registries and study population
The Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) is a longitudinal, observational database of men with biopsy-proven prostate cancer recruited from a total of 40 urologic practice sites. The majority of sites are community based; four university-affiliated Veterans Affairs (VA) medical centers are included. CaPSURE collects B1000 clinical and patient-reported variables and men are followed until death or study withdrawal. Additional details regarding project methodology have been reported previously. 16 Of 13 821 men registered in the database, 9333 were diagnosed between 1998 and 2006 and were included in time-trend analysis. Of these, 5156 had detailed clinicodemographic data available for multivariate analysis.
The Medicare claims data set includes information from the Medicare Provider Analysis and Review (MEDPAR) and the National Claims History records, and includes enrollment, claims and hospitalization data based on the International Classification of Diseases (ICD-9, 9th revision) and procedure codes using the Current Procedural Terminology coding system (4th edition, CPT-4). Medicare does not include clinical information, such as stage or grade, required for tumor risk stratification. Between 1998 and 2006, 77 216 men were diagnosed with prostate cancer via report of both ICD-9 code 185 and CPT codes for either a prostate biopsy or a TURP within 180 days of the ICD-9 code report using a 5% Medicare sample. Men under age 66 were excluded, as were those not covered continuously by Medicare Part A&B (those with Medicare managed care coverage were also excluded). Of the remaining 55 395, 1073 managed primarily with orchiectomy were excluded for presumed metastatic disease, leaving 54 322 in the final cohort.
The i3 database (Ingenix, Salt Lake City, UT, USA) contains medical claims providing use and cost data on privately insured individuals of 75 large employers. Between 2002-2006, 63 150 men were diagnosed with prostate cancer as confirmed by the ICD-9 and CPT codes described above. As with the Medicare cohort, those managed primarily with orchiectomy or chemotherapy were excluded, as were those with discontinuous insurance coverage between the interval from 6 months before to 18 months after primary treatment. A total of 16 161 men met these criteria and were included in the analyses.
Data analysis
Demographic data available for all three cohorts included age, race, place of residence and primary treatment. Additional clinical information for the CaPSURE cohort included PSA, Gleason grade, clinical stage, insurance type, education level and household income. For CaPSURE, these clinical variables were used to stratify patients into clinical risk groups using the well-validated Cancer of the Prostate Risk Assessment (CAPRA) score. 17 Imaging tests in CaPSURE are reported directly by treating clinicians. In the Medicare and i3 databases, CPT codes were searched to identify BSs (CPT 78306), CT scans (CPT 72192, 72193, 72194) and MRI scans (CPT 72195, 72196, 72197). Imaging utilization for all three tests in all three groups was determined if a test was performed during the staging interval, defined as the period between diagnosis of prostate cancer and date of initial treatment. For men who were not found to have an associated treatment, the staging interval was defined as 180 days following diagnosis. Misclassification of patients undergoing watchful waiting/active surveillance in this category of patients with no treatment was minimized by ensuring there was no evidence of further follow-up. Among men who underwent treatment with any form of radiation therapy, pre-treatment dosimetry planning imaging was distinguished from staging imaging via different CPT codes and excluded.
The rates of BS, CT and MRI were determined in each cohort of men, and time trends were analyzed by linear regression. For men in CaPSURE, demographic and clinical predictors of test utilization were explored using a multivariable regression model. All analyses were performed using Stata statistical software, version 10.1 (StataCorp LP, College Station, Texas, USA). Table 1 lists comparative demographics for each of the study cohorts. The majority of patients in all three cohorts were white. The CaPSURE and i3 cohort had similar age distributions, whereas those covered by Medicare were older by definition. The Medicare and i3 populations had greater distributions of patients residing in southern states as compared with CaPSURE, which had more patients from the northeast. Table 2 further describes the clinical characteristics available for the CaPSURE cohort. Overall, most men had favorable risk characteristics and clinically localized disease.
RESULTS
Figure 1a depicts time trends in imaging utilization of all three study populations. Since 1998, there was a significant downward trend in BS use within the CaPSURE cohort ( À 2% per year, À 16% overall). However, CT and MRI use had a much smaller downward trend at À 0.3% per year, À 2.4% overall for CT and À 0.2% per year, À 1.7% overall for MRI. These trends are mirrored when analysis was restricted to patients with low-risk disease only ( Figure 1b) . Conversely, BS, CT and MRI use all increased by 0.2, 1.3 and 0.2% annually (overall increase 2.1, 10.8 and 2.2%) in Medicare patients and 1.8, 2.1 and 0.8% annually (overall increase 7.9, 8.9 and 3.7%) in privately insured patients, respectively.
Among CaPSURE patients, when stratified by CAPRA risk group, the use of any imaging test was greater in men with higher-risk disease (Table 3) . Treatment type was found to affect the use of imaging modality, with men undergoing brachytherapy and external beam radiation therapy having significantly greater odds of BS (odds ratio (OR) 1.64 and 1.49) and CT (OR 1.72 and 1.39) compared with men treated with androgen deprivation therapy (ADT) (OR 0.42 and 0.53) and watchful waiting active surveillance (OR 0.53 and 0.24) who were less likely to have imaging using either of these modalities. Among men who were imaged with MRI, only those treated with brachytherapy were significantly more likely to undergo imaging (OR 1.83). In addition, men with VA coverage were less likely to have BS (OR 0.29) or a CT (OR 0.35). Age at diagnosis, race, level of education and income were not significantly associated with a specific imaging pattern (data not shown).
DISCUSSION
Imaging studies are performed in men diagnosed with prostate cancer to help provide accurate staging and guide treatment decisions. However, in the era of widespread PSA screening, there has been a profound downward stage migration leading to earlier detection of mostly (80%) clinically localized disease. 18 BS has been shown to have little utility in men with clinically localized disease. In the early 1990s, Osterling et al. 19 reported that in over 2000 men with PSA o20 ng ml À 1 , 0.3% had a positive BS. Since that time, this finding has been confirmed by multiple groups. [20] [21] [22] Multiple investigators have likewise affirmed the lack of sensitivity of cross-sectional imaging in determining the extent of disease. Compounded by the low prevalence of detectable lymphadenopathy or nodal metastasis in men with low-risk cancer, the predictive value of these tests is quite low, with sensitivity of 36% overall and 25-45% for detecting lymph node metastases. 1, 23, 24 A meta-analysis of 25 studies-including 1586 men who underwent imaging with staging CT-found that among men with PSA o20 ng ml À 1 , CT-documented lymphadenopathy was found in none and identification of localized disease in 0.7%. 20 MRI was initially thought to be a promising, albeit costly, technology in pre-treatment staging of prostate cancer. Reported rates for sensitivity and specificity in detecting extraprostatic Currently, the clinical utility of a routine MRI is unclear in the staging of a low-risk prostate cancer patient, and such testing is in most cases not indicated. Despite these consistent research findings in large cohorts and well-established practice guidelines, multiple recent studies have repeatedly identified overutilization of imaging in men with lowrisk disease. [11] [12] [13] 27, 28 An initial analysis using CaPSURE data in the 1990s highlighted the widespread overuse in the rates of imaging among patients with low likelihood of nonlocalized disease. 29 However, a follow-up analysis reporting data through 2001 showed that rates of BS and CT use subsequently decreased markedly with the greatest decreases (63%) in patients with low- Figure 1 . (a) Depicts time trends in imaging utilization of all three study populations. Since 1998, there was a significant downward trend in BS use within the CaPSURE cohort ( À 2% per year, À 16% overall). However, CT and MRI use had a much smaller downward trend at À 0.3% per year, À 2.4% overall for CT and À 0.2% per year, À 1.7% overall for MRI. These trends are mirrored when analysis was restricted to patients with low-risk disease only (b). BS, bone scan; CT, computed tomography; MRI, magnetic resonance imaging.
risk disease. 8 In the current analysis, BS use continued to fall, and any imaging test use was appropriately associated with a greater likelihood of higher-risk disease. For MRI and CT scan, a weak downward trend continued. A similar trend was observed when restricted to men with only low-risk disease. On the other hand, we found in both men insured by Medicare or privately insured the rates of all imaging tests have increased, with the largest increases in CT scan use (up to 11%). The difference in findings may reflect inherent differences between cohorts. CaPSURE is not a population-based cohort and includes relatively highvolume practices that may reflect guideline-based practice to a greater extent than the average practitioner represented in Medicare or i3. Further investigation is needed to explore our observed differences.
In another Medicare study, the annual increase of BS, CT and MRI use for prostate cancer from 1999 to 2006 was 2.5, 4.6 and 6.2%, respectively, similar to the trends observed in our Medicare and i3 cohorts. 13 A key difference between that paper and the present analysis is that it included any scans ordered within 2 years of diagnosis, many of which may not have been performed for purposes of staging.
When focusing on the CaPSURE cohort, for whom more detailed clinical data were available, we found that treatment type and VA insurance were predictive of imaging use. Even with adjustment for disease risk, men who were treated with brachytherapy and external beam radiation therapy had approximately twice the likelihood of undergoing BS and CT than men treated with prostatectomy, echoing our findings in 2002. 8 Men on watchful waiting active surveillance had lower likelihood of BS and CT, as would be expected. Men who were treated with ADT, monotherapy, also had lower probability of BS and CT. This is somewhat surprising, as men who treated with ADT are more likely to have high-risk disease. One explanation is that men who are not high risk are inappropriately treated with ADT, but appropriately not imaged. Alternatively, highrisk men may be receiving treatment without adequate staging or with the assumption that further imaging would not alter treatment if systemic therapy was administered. Men who elected brachytherapy also had higher odds of MRI imaging.
Another recent cross-sectional analysis of men with newly diagnosed prostate cancer from 2004 to 2005 using SEERMedicare linked data parallel to our findings of imaging overuse and misuse. 28 Approximately one-third of patients with low-risk disease and 48% with intermediate-risk disease underwent imaging, compared with only 60% of men with high-risk disease. As with the CaPSURE cohort, radiation therapy was significantly associated with a higher odds of imaging (OR 1.71, 95% CI 1.60-1.84), whereas AS was associated with lower odds of imaging (OR 0.17, 95% CI 0.15-0.19). That study did not find a negative association with ADT as in the present analysis, but rather observed increased odds of imaging in men with greater household income. The minor differences in our findings are likely attributable to the differences in patient cohorts and selection.
Interestingly, men who had VA insurance were less likely to have BS and CT imaging in the CaPSURE population. In the VA system, there is no financial incentive for test utilization, which may account for the lower odds of imaging as compared with other insurance groups where reimbursements for diagnostic testing may drive imaging use. 30 This is only one hypothesis to the reason behind inappropriate imaging utilization and further study is needed to determine all factors that lead to misuse. In fact, a recent study including men treated at two VA Hospitals found that 25% of patients with low-risk prostate cancer had underwent BSs, none with positive findings. 27 In the VA study, white men with low-risk disease were more likely to have a BS than their black counterparts. Our analysis conversely did not confirm any association between race and overutilization.
Overuse of imaging is associated with significant costs to both the healthcare system and patient safety. In addition to reporting increased utilization of imaging tests in Medicare beneficiaries, Dinan et al. 13 showed that imaging costs in patients with prostate cancer have risen at a rate far outstripping that of overall cost of care, increasing annually 45% as compared with a 1.8% rise in total costs. This rate of increase parallels our findings of increased utilization in the Medicare and i3 cohorts. On the basis of 2012 Medicare reimbursement rates (recently reduced by B25%), an abdominal-pelvic CT (single-phase contrast only) costs B$450 (technical fee $356, professional fee $94) (https://www.cms.gov). If 217 730 men are newly diagnosed with prostate cancer, 50% have low-risk disease, and CT imaging occurred in only 20%, an excess of 21 773 tests would be performed. This would translate to nearly $10 million that could be saved yearly, by eliminating unnecessary CT scans alone. Emerging data regarding risks of radiation exposure and patient safety add further importance to this issue. Smith-Bindman et al. 15 recently calculated that radiation doses from abdominal and pelvic CT scans result in a significant attributable risk of subsequent malignancy: for a 60-year-old man, one cancer would occur among 660-1250 patients who underwent a routine abdominal-pelvic CT scan. Again, if 21 773 excess studies are performed yearly using the above estimates, 33 cancers could be prevented simply by eliminating unnecessary CT scans.
Limitations include the retrospective nature of this study as well as specific limitations of each data set. CaPSURE data primarily reflects tests ordered by urologists; tests ordered by other clinicians will be included only if reported by the urologist and/or by the patient. The Medicare and i3 cohorts do not include parameters with regards to disease risk and we assume that as a group our cohorts have experienced the same downward stage migration as the general population. Some of the imaging tests would have been used appropriately for men with high-risk disease. The men in the CaPSURE and i3 study groups were not randomly selected and do not represent a statistical sample of national practice patterns. In addition, we excluded imaging studies associated with pre-treatment planning in men undergoing some form of radiation therapy by defining staging intervals and utilizing differential CPT and ICD-9 procedure codes. However, a small proportion of men who underwent imaging might have been wrongly classified as 'staging', therefore increasing the number of patients in this category.
It is unclear what factors underlie persistent overuse of imaging in men with clinically localized prostate cancer, but possible contributing factors include financial incentives favoring testing, overtesting as a form of 'defensive medicine' against fears of malpractice suits, slow dissemination of findings and guidelines to community practitioners, and patient expectations and demands. In fact, the Centers for Medicare and Medicaid's 2010 Physician Quality Reporting System (PQRS) selected non-utilization of BS among low-risk patients as one of the only three indicators of high-quality prostate cancer care; reducing unnecessary imaging for low-risk disease is also one of the five initiatives identified in the Choosing Wisely program by the American Urologic Association and the American Board of Internal Medicine foundation (http://www.choosingwisely.org/doctor-patient-lists/american-urological-association/). 31 In addition, Miller et al. recently reported on a Urological Surgery Quality Collaborative project centered on improving adherence to imaging guidelines for men newly diagnosed with prostate cancer. 32 Using important quality improvement tools like performance feedback and dissemination of guidelines, a significant reduction in inappropriate use for BS and CT was observed in patients with low-and intermediate-risk prostate cancer. Eventually, payors may simply stop reimbursing imaging tests in situations such as low-risk prostate cancer in which they are not indicated clearly.
CONCLUSION
Overutilization of imaging is a remarkably pervasive and persistent phenomenon in localized prostate cancer-verified in this analysis in multiple large data sets and apparently worsening despite the downward risk migration of the disease. The upward trend is greatest for CT, with substantial resulting costs and risks. These findings highlight the need for a re-examination of the financial incentives and other factors that drive decision making regarding staging test utilization.
